Roche Considers Pricing Flexibility For Avastin In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Similar to Genentech’s price cap on Avastin in the U.S., Roche is evaluating “creative” pricing approaches following breast cancer approval.
You may also be interested in...
Genentech Resubmits Avastin sBLA For Metastatic Breast Cancer
The targeted oncologic is simultaneously approved in Europe for first-line treatment of patients with advanced non-small cell lung cancer.
Genentech Resubmits Avastin sBLA For Metastatic Breast Cancer
The targeted oncologic is simultaneously approved in Europe for first-line treatment of patients with advanced non-small cell lung cancer.
Genentech Plans Avastin Breast Cancer Resubmission In August
Company expects a six-month review for the supplemental claim, setting early 2008 for potential FDA approval.